Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer
Abstract We here investigate the expression of the mitochondrial carrier homolog 2 (MTCH2) and its potential function in castration-resistant prostate cancer (CRPC). Bioinformatic analyses reveal that MTCH2 overexpression is associated with critical clinical parameters of prostate cancer. Single-cel...
Saved in:
Main Authors: | Yankui Liu, Anjie Chen, Yufan Wu, Jiang Ni, Rong Wang, Yong Mao, Ning Sun, Yuanyuan Mi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-02-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-025-07406-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New Therapeutics to Treat Castrate-Resistant Prostate Cancer
by: Ömer Acar, et al.
Published: (2013-01-01) -
Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
by: Joelle El-Amm, et al.
Published: (2013-01-01) -
Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01) -
New Horizons In The Treatment Of Metastatic Castrate Resistant Prostate Cancer
by: Zein El Amir
Published: (2023-06-01) -
Mitochondrial Dysfunction and Therapeutic Targets in Auditory Neuropathy
by: Baoyi Feng, et al.
Published: (2020-01-01)